{{medical}}
{{Drugbox
| verifiedrevid = 444216523
| IUPAC_name =  
| image = Teriparatide.png

<!--Clinical data-->
| tradename = Forteo
| Drugs.com = {{drugs.com|monograph|teriparatide}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = C
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = SubQ

<!--Pharmacokinetic data-->
| bioavailability = 95%
| protein_bound =  
| metabolism = Hepatic (nonspecific proteolysis)
| elimination_half-life = SubQ: 1 hour
| excretion = Renal (metabolites)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 52232-67-4
| ATC_prefix = H05
| ATC_suffix = AA02
| PubChem = 16133850
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06285
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 10T9CSU89I
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06078

<!--Chemical data-->
| chemical_formula =  
 | C=181 | H=291 | N=55 | O=51 | S=2 
| molecular_weight = 4117.72 g/mol
}}

'''特立帕肽'''（Forteo）为重组的[[甲状旁腺激素|甲状旁腺激素]]，用于治疗一些类型的[[骨质疏松|骨质疏松]]。<ref name="pmid18003959">{{cite journal |author=Saag KG, Shane E, Boonen S, ''et al.'' |title=Teriparatide or alendronate in glucocorticoid-induced osteoporosis |journal=The New England journal of medicine |volume=357 |issue=20 |pages=2028–39 |pmid=18003959 |doi=10.1056/NEJMoa071408 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18003959&promo=ONFLNS19 |date=November 2007 |access-date=2011-11-08 |archive-date=2019-12-15 |archive-url=https://web.archive.org/web/20191215191240/http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18003959&promo=ONFLNS19 |dead-url=no }}</ref>

== 用途 ==
特立帕肽适用于患严重[[骨质疏松|骨质疏松]]的患者，目前也正在进行评价该药对于治疗成骨不全症方面的药效的临床试验。<ref name="Ref_">{{Cite web |url=http://www.clinicaltrials.gov/ct/show/NCT00131469 |title=Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta - Full Text View - ClinicalTrials.gov<!-- Bot generated title --> |access-date=2011-11-08 |archive-date=2016-05-13 |archive-url=https://web.archive.org/web/20160513233931/https://clinicaltrials.gov/ct/show/NCT00131469 |dead-url=no }}</ref>

不应給存在增高的患[[骨肉瘤|骨肉瘤]]风险的患者开用特立帕肽。这样的患者包括[[佩吉特氏骨病|佩吉特氏骨病]]（Paget's Disease of bone，畸形性骨炎）的患者、未能解释的[[血清|血清]]碱性磷酸酶升高的患者、[[骺板|骺板]]尚未闭合的患者，或涉及到骨骼的[[放射性治疗|放射性治疗]]前的患者。

== 副作用 ==
最常见的副作用是[[恶心|恶心]]、腿[[抽筋|抽筋]]和[[眩晕|眩晕]]。使用特立帕肽的主要风险是增加罹患[[骨肉瘤|骨肉瘤]]的機率，至少在[[大鼠|大鼠]]的实验研究中见到的结果是这样。在该药物上市后，已经有非常少的关于患[[骨肿瘤|骨肿瘤]]和骨肉瘤的病例报道。<ref name="Ref_a">{{Cite web |url=http://www.drugs.com/pro/forteo.html |title=存档副本 |accessdate=2011-11-08 |archive-date=2018-06-15 |archive-url=https://web.archive.org/web/20180615135231/https://www.drugs.com/pro/forteo.html |dead-url=no }}</ref>

== 作用机制 ==
特立帕肽是人类甲状旁腺激素（PTH）的一部分，[[氨基酸|氨基酸]]序列的1到34（完整的人类甲状旁腺激素含84个氨基酸）。内源性的甲状旁腺激素是[[骨|骨]]和[[肾|肾]]中钙磷[[代谢|代谢]]的主要调节因子。PTH增加血清中的钙浓度，伴随着钙浓度的增加，骨头对钙的吸收也有部分的增加。这样，长期地PTH的升高，将消耗骨储存。然而，间断地接触PTH将激活成骨细胞，使之多于破骨细胞。这样，每天一次注射特立帕肽具有次级新骨形成的净效果导致骨中无机质密度的增高。<ref name="Ref_b">Bauer E, Aub JC, Albright F. Studies of calcium and phosphorus metabolism: V. Study of the bone trabeculae as a readily available reserve supply of calcium. J Exp Med. 1929;49:145-162.</ref><ref name="Ref_c">Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology. 1932;16:547-558.</ref><ref name="Ref_d">Dempster, D.W., Cosman, F., Parisien, M., Shen, V., & R. Lindsay.  [http://edrv.endojournals.org/cgi/content/abstract/14/6/690 “Anabolic actions of parathyroid hormone on bone.”] {{Wayback|url=http://edrv.endojournals.org/cgi/content/abstract/14/6/690 |date=20090627143022 }}  (1993).  Endocrine Review: 14(6): 690-709.</ref>

特立帕肽是第一个，也是到目前為止唯一的一個經FDA批准用于治疗[[骨质疏松症|骨质疏松症]]、刺激新骨形成的药物。<ref name="Ref_e">[http://www.forteo.com/secure/user/index.jsp Fortéo: teriparatide (rDNA origin) injection] {{webarchive|url=https://web.archive.org/web/20091227173148/http://www.forteo.com/secure/user/index.jsp |date=2009-12-27 }}</ref>

== FDA审批 ==
[[美国食品药品监督管理局|美国食品药品监督管理局]]于2002年11月26日批准了特立帕肽用于治疗男人和绝经期妇女具有高度骨折风险的骨质疏松症。也用于治疗男性原发或由于性机能减退造成的具有高骨折风险的骨质疏松。

== 参考文献==
{{reflist}}

{{Peptidergics}}

[[Category:药物|Category:药物]]
[[Category:礼来公司|Category:礼来公司]]